catalyst timeline

Key upcoming catalysts and milestones that could drive share price re-rating, with estimated timing and probability-weighted impact.

near-term catalysts

4

next 6 months

medium-term catalysts

3

6-18 months

highest impact

ASCO 2026

oncology data readouts

Exhibit 1: Catalyst Calendar

date	catalyst	category	expected impact	probability
oct 11, 2024 (historical)	hympavzi pdufa decision (completed: approved)	regulatory	moderate	65%
apr 2026	q1 2026 earnings + updated guidance	earnings	high	100%
jun 2026	asco 2026 oncology data readouts	pipeline	high	90%
h2 2026	seagen synergy milestone update	m&a integration	high	80%
q4 2026	padcev combination phase iii results	pipeline	very high	70%
2027	tivdak expanded indications filing	regulatory	moderate	55%
2027-2028	next-gen immunotherapy ind filings	pipeline	moderate	45%

Catalyst Concentration: The next 12 months present a dense catalyst window, with ASCO 2026 and the Seagen synergy update representing the two highest-impact events. Positive outcomes at either could drive a 10-15% re-rating; failures would likely compress the multiple toward the bear case.

See detailed catalyst analysis in catalysts tab